Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Discovery of monoclonal antibodies which may make a successful Hepatitis C vaccine a reality

Hepatitis C Virus (HCV) infects up to 500,000 people in the UK alone, many of the infections going undiagnosed.

4 Sep 2007

Radiation and drug combo helps boost efficacy of lung cancer treatment

Combining radiation therapy with a drug that helps destroy blood vessels nourishing malignant tumors has been shown in mice to be significantly more effective in treating lung cancer than either approach alone, researchers at UT Southwestern Medical Center have found.

3 Sep 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

New findings on gene-transcription machinery

For some time, scientists have been tracking down the sequence of biochemical steps required to attract and assemble at the head end of a gene the molecular machinery needed to transcribe that gene to put to work the information it encodes.

26 Jul 2007

Biologic agents valuable treatment option for patients with inflammatory bowel disease

The use of biologic agents for the treatment of inflammatory bowel disease (IBD) may benefit patients, but doctors need to consider the potential associated side effects in determining treatment course, according to a consensus paper published in this month's issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

26 Jul 2007

New combo treatment for chronic lymphocytic leukaemia increases survival

The combination treatment of fludarabine plus cyclophosphamide for chronic lymphocytic leukaemia (CLL) greatly increases progression-free survival and response rates, compared with single treatment with either fludarabine or chlorambucil alone.

20 Jul 2007

New advance in search for effective treatment for human liver cancer

Researchers from the University of Pittsburgh School of Medicine report a significant new advance in the search for an effective treatment for human liver cancer in the July issue of Molecular Cancer Therapeutics.

12 Jul 2007

MacroGenics investigational new drug for West Nile vrus monoclonal antibody is active

MacroGenics has announced that the company's investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody targeted to West Nile Virus is now active.

10 Jul 2007

Pieris progresses proprietary asthma program

Pieris AG, a bio-pharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma.

10 Jul 2007

Trastuzumab and chemo improves survival in women with operable HER-2 positive breast cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

9 Jul 2007

Mushrooms show promise for creation of new drugs

Mushrooms might serve as biofactories for the production of various beneficial human drugs, according to plant pathologists who have inserted new genes into mushrooms.

23 Jun 2007

Results of Tocilizumab study

Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement, according to results of a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007

Bone erosion reduced by denosumab

Treatment with denosumab 60 mg and 180 mg (with background methotrexate) reduces the progression of bone erosion according to results of a 227 patient Phase II trial presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

19 Jun 2007

Women well-informed about breast cancer although lack knowledge about current treatments

According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.

16 Jun 2007

Study finds lymphoma drug effective over long term

Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University of Michigan Comprehensive Cancer Center.

5 Jun 2007

Study shows combination improves survival of metastatic melanoma patients

Two chemotherapy drugs combined with an agent that prevents the growth of blood vessels significantly delayed the spread of tumors in patients with metastatic melanoma, according to study findings presented at the 2007 American Association of Clinical Oncology (ASCO) Annual Meeting.

5 Jun 2007

Benefits of Herceptin are lasting

An updated analysis of two large randomized clinical trials has found that breast cancer patients who received the monoclonal antibody trastuzumab (Herceptin) along with chemotherapy are living longer and with less risk of recurrent disease, compared to patients treated with chemotherapy alone.

5 Jun 2007

Adding radioimmunotherapy to chemo may help patients with lymphoma

Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkin's lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings.

5 Jun 2007

Study tests oral insulin to prevent type 1 diabetes

University of Florida researchers have begun a clinical study of oral insulin to prevent or delay type 1 diabetes in people at risk for the disease.

3 Jun 2007

Human antibodies protect mice from H5N1 avian influenza

An international team of scientists, including researchers from the National Institute of Allergy and Infectious Diseases (NIAID), report using antibodies derived from immune cells from recent human survivors of H5N1 avian influenza to successfully treat H5N1-infected mice as well as protect them from an otherwise lethal dose of the virus.

30 May 2007